Lion Point Capital, LP Ardelyx, Inc. Transaction History

Lion Point Capital, LP

$10.5 Million
Q3 2025

A detailed history of Lion Point Capital, LP transactions in Ardelyx, Inc. stock. As of the latest transaction made, Lion Point Capital, LP holds 162,750 shares of ARDX stock, worth $955,342. This represents 8.52% of its overall portfolio holdings.

Number of Shares

162,750

Previous 335,400 51.48%

Holding current value

$955,342

Previous $1.31 Million 31.66%

% of portfolio

8.52%

Previous 14.76%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$3.92 - $6.64 $676,788 - $1.15 Million	-172,650 Reduced 51.48%	162,750 $898,000
Q4 2024 Feb 14, 2025	SELL	$4.49 - $6.85 $155,354 - $237,010	-34,600 Reduced 9.35%	335,400 $1.73 Million
Q3 2024 Nov 14, 2024	SELL	$5.28 - $7.57 $2.57 Million - $3.68 Million	-486,667 Reduced 56.81%	370,000 $2.55 Million
Q2 2024 Aug 14, 2024	SELL	$5.89 - $9.31 $1.12 Million - $1.77 Million	-190,000 Reduced 18.15%	856,667 $6.35 Million
Q1 2024 May 15, 2024	SELL	$6.05 - $9.74 $635,250 - $1.02 Million	-105,000 Reduced 9.12%	1,046,667 $7.64 Million

Q4 2023 Feb 14, 2024	SELL	$3.29 - $6.64 $82,250 - $166,000	-25,000 Reduced 2.12%	1,151,667 $7.14 Million
Q3 2023 Nov 14, 2023	SELL	$3.3 - $4.83 $1.16 Million - $1.69 Million	-350,000 Reduced 22.93%	1,176,667 $4.8 Million
Q2 2023 Aug 14, 2023	SELL	$3.23 - $4.95 $1.65 Million - $2.52 Million	-510,000 Reduced 25.04%	1,526,667 $5.18 Million
Q1 2023 May 15, 2023	BUY	$2.68 - $4.79 $406,467 - $726,484	151,667 Added 8.05%	2,036,667 $9.76 Million
Q4 2022 Feb 14, 2023	BUY	$1.22 - $2.85 $1.63 Million - $3.8 Million	1,335,000 Added 242.73%	1,885,000 $5.37 Million
Q3 2022 Nov 14, 2022	BUY	$0.59 - $1.44 $324,500 - $792,000	550,000 New	550,000 $666,000

Others Institutions Holding ARDX

# of Institutions

244

Shares Held

161M

Call Options Held

697K

Put Options Held

1.61M

View Full List

About ARDELYX, INC.

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $908M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

More about ARDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lion Point Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Lion Point Capital, LP with notifications on news.

Account

Lion Point Capital, LP Ardelyx, Inc. Transaction History